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The final steps in the production of adenosine triphosphate (ATP) in mitochondria are executed by a series of multisubunit
complexes and electron carriers, which together constitute the oxidative phosphorylation (OXPHOS) system.OXPHOS is un-
der dual genetic control, with communication between the nuclear andmitochondrial genomes essential for optimal assem-
bly and function of the system. We describe the current understanding of the metabolic consequences of pathological
OXPHOS defects, based on analyses of patients and of genetically engineeredmodel systems. Understanding themetabolic
consequences of OXPHOS disease is of key importance for elucidating pathogenic mechanisms, guiding diagnosis and de-
veloping therapies.Introduction
The aerobic production of ATP involves the cellular uptake and
transport of substrates, their metabolic conversion, and a multi-
tude of accessory systems, many of which act in a cell-, tissue-,
or system-dependentmanner. The synthesis of ATP in the termi-
nal biochemical pathway, oxidative phosphorylation (OXPHOS),
is driven by the energy released during the stepwise oxidation of
electron carriers reduced by the catabolism of carbohydrates,
fats and amino acids (Figure 1). Genetic defects of OXPHOS
are now recognized as important causes of disease (see recent
reviews by Smeitink et al., 2001; Zeviani and Di Donato, 2004;
Taylor and Turnbull, 2005; DiMauro and Davidzon, 2005). Here,
we review the main metabolic consequences of OXPHOS im-
pairment, including accumulation ofmetabolic intermediates, in-
creased generation of reactive oxygen species (ROS), and de-
creased ATP production.
The OXPHOS system
OXPHOS requires the orchestrated action of a series of multihe-
teromeric enzyme complexes located in the inner mitochondrial
membrane (Saraste, 1999; Smeitink et al., 2001). These com-
prise the proton-translocating respiratory chain complexes I,
III, and IV, the proton-utilizing ATP synthase, or complex V, plus
a set of accessory complexes that supply electrons to coenzyme
Q (ubiquinone), including complex II (succinate-ubiquinone
oxidoreductase), the electron-transfer flavoprotein-ubiquinone
oxidoreductase (ETF-QO), and dihydroorotate dehydrogenase.
Mitochondrial DNA (mtDNA) encodes only 13 of thew85 poly-
peptides comprising the OXPHOS complexes (subunits of com-
plexes I, III, IV, and V), plus two ribosomal and 22 transfer RNAs
required for the partially autonomousmitochondrial translational
apparatus (Taylor and Turnbull, 2005). All other mitochondrial
proteins, including those required for mtDNA maintenance and
expression, OXPHOS assembly and biosynthesis of cofactors
such as heme and Fe-S clusters, are nuclear coded and im-
ported to mitochondria.CELL METABOLISM 3, 9–13, JANUARY 2006 ª2006 ELSEVIER INC. DOXPHOS disorders
OXPHOS disorders can be classified genetically according to
whether the primary defect is in the nuclear or mitochondrial ge-
nome, as well as by the pathway primarily affected (Table 1).
There remains a considerable lack of understanding of the path-
ogenic mechanisms involved in the development of clinical
symptoms and the deterioration seen inmany patients. The cen-
tral role of OXPHOS in metabolism suggests that many of these
features are related to abnormal metabolic consequences of the
defects.
To understand these processes it is important to recognize
some key features of OXPHOS genetics. The mtDNA is found
in high copy number (w103/cell or more). Mutations can affect
all mtDNA copies in an individual (homoplasmy) or only some
copies (heteroplasmy). In cases of heteroplasmy, there is typi-
cally a threshold mutation level required for the expression of
a biochemical defect in individual cells. This means that within
a tissue, there may be a mixture of respiratory competent and
deficient cells (Taylor and Turnbull, 2005).
In addition, OXPHOS defects can be tissue specific, due to
the variable metabolic thresholds for the different OXPHOS en-
zyme complexes in each tissue (Rossignol et al., 2000). Tissue
specificity may limit the systemic effect of metabolic changes
while still inducing marked abnormalities within the affected tis-
sue. There are, however, likely to be many contributing factors
including tissue-specific expression of nuclear OXPHOS genes,
different metabolic needs of a tissue (for example, burst activity
seen in some neurons versus cells with predominantly continu-
ous biosynthetic functions), and tissue-dependent segregation
of heteroplasmy (Battersby et al., 2003).
Metabolic consequences of OXPHOS disease
Systemic consequences of OXPHOS dysfunction
Increased concentrations of organic acids (particularly lactic
acid and TCA cycle intermediates) in blood, urine, cerebrospinalOI 10.1016/j.cmet.2005.12.001 9
M I N I R E V I E WFigure 1. Mitochondrial energy metabolism
Schematic representation of mitochondrial energy metabolism and related pathways. I, II, III, IV, and V, complexes I–V. Complexes II, III, and IV are shown as functionally
active dimers. SOD2, superoxide dismutase 2; GPx, gluthatione peroxidase; ANT, adenine nucleotide translocator; TCA, tricarboxylic acid; b-oxidn, b-oxidation; PDH,
pyruvate dehydrogenase complex; Ac-CoA, acetyl-CoA; DHODH, dihydroorotate dehydrogenase; GPT, glutamic pyruvic transaminase; LDH, lactate dehydrogenase;
AIF, apoptosis inducing factor; CAD, caspase-acitivated DNase; Q, coenzyme Q (ubiquinone); QH2, reduced coenzyme Q (ubiquinol); cred and cox, reduced and oxidized
forms, respectively, of cytochrome c; ADP, adenosine diphosphate; ATP, adenosine triphosphate; NAD+ and NADH, oxidized and reduced forms, respectively, of nico-
tinamide adenine dinucleotide, GSH and GS-SG, reduced and oxidized forms, respectively, of glutathione. MtDNA-encoded subunits are shown in blue, membrane trans-
porters in green, the apoptosis-related protein Apaf-1 in cream, other enzymes and pathways in orange. Different metabolic pathways are depicted in different areas of the
mitochondrial matrix and inner membrane compartments purely for illustrative purposes. The left-hand area shows Ca2+ transport and the respiratory chain enzymes that
are involved in the production of ROS or interacting with other electron carriers, i.e., coenzyme Q and cytochrome c. Themiddle area shows the main mitochondrial energy
pathways. Pyruvate, which stands at the crossroads of glycolysis, gluconeogenesis and OXPHOS, is the key intermediate in carbohydrate oxidation and feeds into the TCA
cycle via the pyruvate dehydrogenase complex (PDH) to generate acetyl-CoA. Fatty acids are oxidized within the mitochondrial matrix by b-oxidation, which again gen-
erates acetyl-CoA for the TCA cycle. Reducing equivalents generated during the oxidation of the primary substrate or from the TCA cycle are transferred to OXPHOS as
NADH (at complex I), or reduced flavins (entering at complex II or III). The right-hand area shows the action of DHODH and its dependence upon coenzyme Q-mediated
electron transfer. Components of the mitochondrial apoptotic pathway (AIF, cytochrome c, CAD) are located in the intermembrane space and, upon pro-apoptotic signal-
ing, are released through the permeability transition pore, comprising modified and juxtaposed ANT and porin (VDAC) channels, or via other outer membrane pores, to
induce caspase activation in the cytosol.fluid, as well as in tissues, are frequently encountered in patients
with OXPHOS deficiencies, especially in children and in those
with the most severe biochemical defects (Smeitink, 2003;
Esteitie et al., 2005). Increased lactic acid production is thought10to result from pyruvate accumulation and the altered cellular re-
dox state, under conditions where the TCA cycle and OXPHOS
system are inhibited. This shifts the equilibrium of the pyruvate-
lactate reaction catalyzed by the NADH-dependent lactateCELL METABOLISM : JANUARY 2006
M I N I R E V I E Wdehydrogenase. Overproduction of lactic acid may cause lac-
tic acidosis, resulting in a global disturbance of cellular pH
(Munnich et al., 1992). In a subset of patients, the ketone body
(b-hydroxybutyrate/aceto-acetate) ratio is also increased, due
to the altered NADH/NAD+ ratio (Munnich et al., 1992).
The blood concentration of alanine is increased in most pa-
tients with OXPHOS disorders. Like the organic acid lactate,
this amino acid is converted from pyruvate under conditions of
metabolic disturbance, since the equilibrium of the alanine ami-
notransferase reaction is dependent on pyruvate levels. Of the
other amino acids, abnormal levels of proline and citrulline may
also result from OXPHOS deficiency, although such alterations
are less frequently observed. Proline oxidation is hampered by
increased concentrations of lactic acid, leading to increased
proline concentration. Very low citrulline concentrations have
also been described in some patients with mitochondrial dis-
ease (Rabier et al., 1998).
Defective OXPHOShas also been suggested as a global path-
ogenic mechanism in diabetes. Diabetes, with variable onset
and insulin responsiveness, is a common feature in patients with
OXPHOS disorders, and this is almost certainly due primarily to
impaired insulin secretion from pancreatic b cells, arising from
defective glucose signaling (Walker et al., 2005). Interestingly,
recent evidence indicates impaired OXPHOS inmuscle from pa-
tients with type 2 diabetes, suggesting that this may contribute
to the insulin resistance seen in these patients (Petersen et al.,
2005).
Metabolic consequences at the tissue and cellular level
Bioenergy deficiency
An inability of mitochondria to supply sufficient ATP to meet cel-
lular needs is often assumed to be the primary effect of mito-
chondrial disease mutations. However, this may not be the
only or even the major consequence of OXPHOS failure. Cul-
tured cells with a high proliferative capacity, as well as tumor
cells in vivo, subsist essentially on glycolytic ATP production.
Mitochondria contain a system for exchange of adenine nucleo-
tides across the inner mitochondrial membrane, dedicated in
principle to the supply of OXPHOS-generated ATP to the rest
of the cell. However, this system can work equally well in re-
verse, supplying extramitochondrially synthesized ATP to ener-
gize ATP-dependent reactions inside mitochondria. OXPHOS-
derived ATP may thus be essential only in specific cellular or
Table 1. Genetic classification of OXPHOS disease mutations
Defects of mitochondrial DNA
Protein synthesis genes (rRNAs, tRNAs)
Protein-encoding OXPHOS subunit genes
Large deletions
Nuclear DNA mutations
Protein-encoding OXPHOS subunit genes
Genes encoding OXPHOS assembly factors
Genes encoding factors affecting mitochondrial DNA maintenance
Mitochondrial protein synthesis genes (ribosomal proteins, initiation, elongation
and release factors)
Genes modifying mitochondrial tRNA post-transcriptionally
Genes encoding biosynthetic enzymes for lipids or cofactors
For more detail of individual genetic defects, see Zeviani and Di Donato (2004).CELL METABOLISM : JANUARY 2006physiological contexts, for example, in the heart under stress
conditions (see Cabrera et al., 2005).
Redox or metabolite imbalance
Many transport processes of mitochondria are directly energized
by the electrochemical proton gradient of the innermitochondrial
membrane, which uses a significant proportion of the free energy
conserved by biological oxidations (Palmieri et al., 2000). This
concerns not only the import and export of key metabolites but
also of inorganic ions such as phosphate, sodium, potassium,
or calcium (Nguyen and Jafri, 2005; Szabo et al., 2005). Calcium
is a highly versatile intracellular signal that regulatesmany cellular
processeswith variable spatial and temporal dynamics (Berridge,
2003). Intracellular calcium concentration is generally maintained
within a very narrow range aroundw100 nM. Mitochondria play
a central role in ensuring calcium homeostasis (Nicholls, 2005)
by sequestering transient elevations in cytoplasmic Ca2+. This
homeostasis appears to be disturbed in cells of patients with
OXPHOS disease, as well as in a heart-specific mouse model
of OXPHOS disease (Brini et al., 1999; Visch et al., 2004; Tavi
et al., 2005). In the latter case, there is a clear association with
catecholamine-induced arrhythmias, suggesting that calcium
provides the crucialmechanistic link betweenmitochondrial bio-
energy deficit and the broader physiological abnormality.
OXPHOS also plays a crucial role in the redox, substrate, and
acid-base balance of cells and, by extension, the extracellular
compartments. Inhibition of OXPHOS results in the over-
oxidation of electron carriers downstream of the site of inhibition
and over-reduction of upstream carriers. This may have a range
of specific effects, for example, on nucleoside metabolism.
Dihydroorotate dehydrogenase, one of the accessory enzymes
of OXPHOS that donates electrons to ubiquinone, is required
for pyrimidine biosynthesis. Severe disturbances of OXPHOS
downstream of complex I thus render cells dependent on an
exogenous supply of uridine (Gattermann et al., 2004).
Elevated or disturbed production of ROS
During respiration a low proportion (w0.2%) of molecular oxy-
gen is converted by partial reduction to ROS (superoxide anion,
O22$ and hydrogen peroxide, H2O2, which can then generate
the highly reactive hydroxyl ion, OH$ [Balaban et al., 2005]).
ROS are generated mainly at OXPHOS complexes I and III. Al-
though they can be toxic to the cell, they are also believed to
play a role in diverse signaling pathways. Under normal condi-
tions, ROS can be scavenged by various enzymes, including
the mitochondrial manganese superoxide dismutase and gluta-
thione peroxidase.
The enhanced generation of ROS under conditions of respira-
tory chain blockade is a further mechanism whereby OXPHOS
defects can potentially lead to cellular damage and dysfunction
(Balaban et al., 2005). Specific inhibition of complex I and, to
a lesser extent, cIII results in a large increase in ROS production
(Koopman et al., 2005). Mutations that inhibit complexes IV or V
also produce this effect indirectly, since the accumulation of re-
duced ubiquinone is a potent inducer of ROS production by
complex I. However, mechanisms exist that should alsomitigate
such consequences, either by partially short-circuiting the elec-
trochemical proton gradient through the activity of members of
the uncoupler protein (UCP) family (Brand and Esteves, 2005) or
via the induction of enzymes for ROS detoxification. Conversely,
the high sensitivity to ROS damage of mitochondrial Fe-S11
M I N I R E V I E Wcluster-containing enzymes, notably aconitase and OXPHOS
complexes I-III themselves, may promote a catastrophic cycle
of cellular damage under particular physiological conditions.
The role of ROS in the cellular response to oxygen sensing re-
mains controversial. ROS production by mitochondria seems to
be required for the normal induction of HIF (hypoxia-inducible
factor), which is a master regulator of oxygen-sensitive gene ex-
pression in response to low oxygen levels (Brunelle et al., 2005,
Guzy et al., 2005 and Mansfield et al., 2005). Abnormalities in
ROS production caused by OXPHOS dysfunction could thus
result in aberrant HIF-mediated gene regulation. Such a mecha-
nism has been suggested to underlie the inappropriate prolifer-
ative signaling associated with complex II or fumarase (FH) def-
iciency, either of which promotes tumor formation (Eng et al.,
2003; Pollard et al., 2003). However, recent evidence indicates
instead that this phenomenonmayproceedwithout any increase
in ROS production (Isaacs et al., 2005; Pollard et al., 2005). It can
be considered an example of the Warburg effect, whereby a
switch from dependence upon OXPHOS to glycolysis for ATP
production appears to drive cells into a proliferative state.
Mitochondria produce nitric oxide (NO) via a mitochondrially
localized, calcium-dependent NO synthase (Ghafourifar and
Cadenas, 2005). In turn, NO modulates the activity of complex
IV, preventing calcium overload of mitochondria. However, it
can also react with superoxide anion to promote irreversible
oxidative damage via peroxynitrite formation, which has been
proposed as a mediator of the mitochondrial signal for apopto-
sis. Clearly, defects in complex I or III which promote superoxide
production, in complex IV affecting its regulation by NO, or in
any OXPHOS function in a cell type where mitochondria serve
as the major calcium sink, can upset the fine balance of this reg-
ulation, leading to the derangement of apoptotic decisions as
discussed in the next section.
Apoptotic mechanisms
Mitochondria are a key integration point for signals that influ-
ence cell death and survival, and one of the key electron carriers
of the OXPHOS system, cytochrome c, is released from the mi-
tochondrial intermembrane space to the cytosol as an inducing
event in apoptosis (Green, 2005). In some instances, a functional
OXPHOS system seems to be required for these events to take
place, whereas in others, OXPHOS dysfunction itself sensitizes
cells to apoptosis or can even induce it directly. A more general
view is that OXPHOS dysfunction leads to dysregulation of ap-
optotic decisions, so that some cells commit suicide inappropri-
ately, whereas other cells, which have sustained different kinds
of damage, fail to die when they should, leading to failure of
physiological functions and perhaps also favoring replicative se-
nescence. The intramitochondrial signals influencing apoptosis
may themselves be complex, involving a combination of the sta-
tus of the electrochemical proton gradient, ROS production,
metabolite and ion concentrations, and ATP levels.
Potential of metabolic therapy to treat OXPHOS disorders
The treatment of patients with OXPHOS disease remains very
limited, but counteracting the most damaging metabolic
changes may be beneficial in some patients, and at present is
the mainstay of treatment.
Acute metabolic acidosis resulting from increased lactate
production can be treated in the short-term with sodium bicar-12bonate. Dichloroacetate, which stimulates pyruvate oxidation,
has also been used to lower lactate concentration, but adverse
effects preclude its widespread clinical use (Barshop et al.,
2004). In the particular case of the rare mitochondrial disorder
MNGIE, attributable to a defect in thymidine kinase activity
(Hirano et al., 2005), potentially dangerous nucleoside precur-
sors accumulate. The blood thymidine level may be >50 times
normal, and lowering it by exchange transfusions or by binding
it to a water-soluble compound enabling urinary excretion might
relieve some of the adverse effects.
Cofactors and vitamin supplements are also widely used in
the treatment of OXPHOS disease, but there is little evidence,
apart from anecdotal reports, to support their use. Ubiquinone
and its derivative idebenone could theoretically be effective for
improving OXPHOS or, alternatively, as free radical scavengers.
This treatment is most clearly effective in the small number of
patients who have a specific deficiency of ubiquinone (Salviati
et al., 2005). More recently, antioxidant compounds which are
directly targeted to mitochondria have been shown to be effec-
tive in cultured cell models of OXPHOS disease, and might be
appropriate clinically (James et al., 2005; Koopman et al., 2005).
Supplementation with L-arginine during a stroke-like episode,
observed in some patients with OXPHOS disease, might be
beneficial. This idea is based on the hypothesis that stroke-
like episodes are caused by impaired vasodilation in an intrace-
rebral artery, which may be counteracted by a precursor of the
strong vasodilator nitric oxide, i.e., arginine (Koga et al., 2002).
Concluding remarks
OXPHOS disease is by its nature extremely heterogeneous, as
well as pleiotropic in its effects. Understanding its metabolic
consequences thus requires a multidisciplinary approach com-
bining in vitro assays with in vivo studies on patients and animal
models.Global analytical tools for profilingRNA, protein, andme-
tabolite levels are helping to piece togethermetabolic changes in
response to OXPHOS defects and to sort out those that are fea-
tures of OXPHOS disease in general from those that are charac-
teristic of specific disease entities. In turn, these should inform
newtherapeuticapproaches. Finally, there is increasingevidence
that OXPHOS dysfunction is prominent in several common neu-
rodegenerative disorders, and perhaps in the ageing process
more generally. The lessons learned fromstudying genetic disor-
ders of OXPHOS may thus generate useful insights and even
eventual therapeutic tools to treat age-related disorders such
as Parkinson’s, Alzheimer’s and Huntington’s diseases.
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